We showed that SF3B1 mutant MDS cases tend to have high levels of inflammation, perhaps due to macrophage activation, and thus confers a good prognosis for patients in terms of anti-tumour activity. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.